News
Global pharmaceutical giants make billions of dollars in Australia but pay a fraction of that in tax. They say the price they ...
There is bipartisan consensus that drugs in the U.S. cost a lot more than in other high-income countries; therefore, it is important to comprehend how governmental interventions in other nations can ...
Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...
Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages - including the XFG and NB.1.8.1 variants1 - compared to ...
Breaking the link between prescription drug list prices and compensation to middlemen like pharmacy benefit managers (PBMs) ...
The companies’ new effort would bypass traditional middlemen to cut the drug’s monthly cost from a list price of around $606 ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages including the XFG and NB.1.8.1 variants1 compared to 2024-20 ...
Canada’s government is keeping the price of American-made pharmaceuticals artificially low while U.S. consumers and taxpayers foot the bill, critics say.
Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He has long wanted to more strictly regulate how medicines are promoted.
Pfizer Inc. (NYSE: PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers, had a meeting with the Trump administration to talk about reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results